uric acid has been researched along with Devic Disease in 7 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Previous studies have shown that serum uric acid (UA) modulates outcomes of neurological diseases, although little is known about cerebrospinal fluid (CSF) UA levels in neuromyelitis optica spectrum disorders (NMOSDs)." | 7.85 | Elevated cerebrospinal fluid uric acid during relapse of neuromyelitis optica spectrum disorders. ( Hu, X; Li, H; Li, R; Long, Y; Lu, Z; Peng, F; Qiu, W; Shu, Y; Wang, Y; Zhang, L, 2017) |
| "Although uric acid (UA) concentration has been considered a surrogate marker for monitoring the progression of multiple sclerosis (MS), less is known about the relationship between UA and the progression of neuromyelitis optica (NMO)." | 7.79 | Serum uric acid levels and their correlation with clinical and cerebrospinal fluid parameters in patients with neuromyelitis optica. ( Chen, X; Cui, L; Liu, C; Peng, B; Wang, J; Xu, Y; Zhong, L, 2013) |
| "Uric acid (UA), a product of purine metabolism, is known to be reduced in patients with various neurological disorders including multiple sclerosis (MS)." | 7.78 | Reduced serum uric acid levels in neuromyelitis optica: serum uric acid levels are reduced during relapses in NMO. ( H Lee, K; Kim, BJ; Lee, S; Min, JH; Vincent, A; Waters, P; Y Shin, H, 2012) |
| "Uric acid (UA) has been reported to be reduced in the serum of patients with multiple sclerosis (MS) and optic neuritis (ON)." | 7.76 | Serum uric acid levels and neuromyelitis optica. ( Dai, Y; Deng, X; Hu, X; Jiang, Y; Li, Q; Long, Y; Peng, F; Qiu, W; Wu, A; Zhong, X, 2010) |
| "To investigate serum uric acid (UA) levels and related clinical characteristics of neuromyelitis optica (NMO)." | 7.76 | [Serum uric acid level and related clinical features in neuromyelitis optica]. ( Hao, YG; Hu, WL; Qin, W; Ye, J; You, XF; Zhao, WH, 2010) |
| "Previous studies have shown that serum uric acid (UA) modulates outcomes of neurological diseases, although little is known about cerebrospinal fluid (CSF) UA levels in neuromyelitis optica spectrum disorders (NMOSDs)." | 3.85 | Elevated cerebrospinal fluid uric acid during relapse of neuromyelitis optica spectrum disorders. ( Hu, X; Li, H; Li, R; Long, Y; Lu, Z; Peng, F; Qiu, W; Shu, Y; Wang, Y; Zhang, L, 2017) |
| "Although uric acid (UA) concentration has been considered a surrogate marker for monitoring the progression of multiple sclerosis (MS), less is known about the relationship between UA and the progression of neuromyelitis optica (NMO)." | 3.79 | Serum uric acid levels and their correlation with clinical and cerebrospinal fluid parameters in patients with neuromyelitis optica. ( Chen, X; Cui, L; Liu, C; Peng, B; Wang, J; Xu, Y; Zhong, L, 2013) |
| "Uric acid (UA), a product of purine metabolism, is known to be reduced in patients with various neurological disorders including multiple sclerosis (MS)." | 3.78 | Reduced serum uric acid levels in neuromyelitis optica: serum uric acid levels are reduced during relapses in NMO. ( H Lee, K; Kim, BJ; Lee, S; Min, JH; Vincent, A; Waters, P; Y Shin, H, 2012) |
| "Uric acid (UA) has been reported to be reduced in the serum of patients with multiple sclerosis (MS) and optic neuritis (ON)." | 3.76 | Serum uric acid levels and neuromyelitis optica. ( Dai, Y; Deng, X; Hu, X; Jiang, Y; Li, Q; Long, Y; Peng, F; Qiu, W; Wu, A; Zhong, X, 2010) |
| "To investigate serum uric acid (UA) levels and related clinical characteristics of neuromyelitis optica (NMO)." | 3.76 | [Serum uric acid level and related clinical features in neuromyelitis optica]. ( Hao, YG; Hu, WL; Qin, W; Ye, J; You, XF; Zhao, WH, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, L | 1 |
| Hu, W | 1 |
| Wang, J | 2 |
| Qian, W | 1 |
| Xiao, H | 1 |
| Shu, Y | 1 |
| Li, H | 1 |
| Zhang, L | 1 |
| Wang, Y | 1 |
| Long, Y | 2 |
| Li, R | 1 |
| Qiu, W | 2 |
| Lu, Z | 1 |
| Hu, X | 3 |
| Peng, F | 3 |
| Zhong, X | 2 |
| Deng, X | 2 |
| Wu, A | 1 |
| Li, Q | 1 |
| Jiang, Y | 2 |
| Dai, Y | 1 |
| You, XF | 1 |
| Ye, J | 1 |
| Qin, W | 1 |
| Zhao, WH | 1 |
| Hao, YG | 1 |
| Hu, WL | 1 |
| Yang, Y | 1 |
| Liu, J | 1 |
| Zhu, C | 1 |
| Chen, X | 2 |
| Min, JH | 1 |
| Waters, P | 1 |
| Vincent, A | 1 |
| Lee, S | 1 |
| Y Shin, H | 1 |
| H Lee, K | 1 |
| Kim, BJ | 1 |
| Liu, C | 1 |
| Xu, Y | 1 |
| Cui, L | 1 |
| Peng, B | 1 |
| Zhong, L | 1 |
1 review available for uric acid and Devic Disease
| Article | Year |
|---|---|
Low serum uric acid levels in patients with multiple sclerosis and neuromyelitis optica: An updated meta-analysis.
Topics: Biomarkers; Humans; Multiple Sclerosis; Neuromyelitis Optica; Uric Acid | 2016 |
6 other studies available for uric acid and Devic Disease
| Article | Year |
|---|---|
Elevated cerebrospinal fluid uric acid during relapse of neuromyelitis optica spectrum disorders.
Topics: Adolescent; Adult; Aged; Blood-Brain Barrier; Humans; Middle Aged; Multiple Sclerosis; Neuromyelitis | 2017 |
Serum uric acid levels and neuromyelitis optica.
Topics: Adolescent; Adult; Aged; Brain Infarction; Case-Control Studies; Child; Child, Preschool; China; Coh | 2010 |
[Serum uric acid level and related clinical features in neuromyelitis optica].
Topics: Adolescent; Adult; Aged; Case-Control Studies; Cross-Sectional Studies; Female; Humans; Male; Middle | 2010 |
Low antioxidant status of serum uric acid, bilirubin and albumin in patients with neuromyelitis optica.
Topics: Adult; Bilirubin; Female; Humans; Male; Middle Aged; Neuromyelitis Optica; Oxidative Stress; Serum A | 2012 |
Reduced serum uric acid levels in neuromyelitis optica: serum uric acid levels are reduced during relapses in NMO.
Topics: Adult; Female; Humans; Immunologic Factors; Interferon-beta; Magnetic Resonance Imaging; Male; Middl | 2012 |
Serum uric acid levels and their correlation with clinical and cerebrospinal fluid parameters in patients with neuromyelitis optica.
Topics: Adolescent; Adult; Aged; Biomarkers; Child; Female; Humans; Male; Middle Aged; Neuromyelitis Optica; | 2013 |